Back

SGLT2 inhibitors: a new era in atrial fibrillation prevention?

12 April 2026 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: Pharmacological treatment for atrial fibrillation Arrhythmias, General EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Dominik Linz

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Antifibrotic drugs: the journey to prime time
Doctor S. Matsumoto (Tokyo, JP)
Slides
Presentation thumbnail
The emerging promise of GLP-1 receptor agonists
Professor V. Caso (Perugia, IT)
Slides
Presentation thumbnail
Anti-hypertensive agents: is there a benefit beyond lowering blood pressure?
Professor M. Rienstra (Groningen, NL)
Slides

Access the full session

Session thumbnail
Pharmacological treatment for atrial fibrillation

The Event

Event poster

EHRA 2026

12 April 2026 13:45 CET
You may be interested in
thumbnail
Congress Presentation
The effect of SGLT2 inhibitor on clinical outcomes in patients with type 2 diabetes and atrial fibrillation
26 August 2023
thumbnail
Congress Presentation
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study
9 December 2021
thumbnail
Congress Presentation
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial). a phase III study
27 August 2021
thumbnail
Congress Presentation
Prevention of new-onset heart failure and renoprotective effect with sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources